BioMarin tries to get hemophilia gene therapy back on track with positive data

One year after receiving an experimental gene therapy, adults with severe hemophilia A enrolled in a study run by BioMarin Pharmaceutical were producing blood clotting protein at levels associated with mild disease, according to data released by the Californian biotech on Sunday.